The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation

Autor: Camilla Tøndel, Paul Passier, Otto Stroosma, Malgorzata Baka-Ostrowska, Søren Rittig, Brigitte Bosman, Birgitta Kjaeer, Stacey Tannenbaum, Johan Vande Walle

Publikováno v: Rittig, S, Baka-Ostrowska, M, Tøndel, C, Walle, J V, Kjaeer, B, Passier, P, Bosman, B, Stroosma, O & Tannenbaum, S 2020, ' The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation ', Journal of Pediatric Urology, vol. 16, no. 1, pp. 31.e1-31.e10 . https://doi.org/10.1016/j.jpurol.2019.10.009
Journal of Pediatric Urology

Introduction: Mirabegron, a selective β3-adrenoreceptor agonist, is a well-established alternative to antimuscarinics in adults with overactive bladder (OAB) symptoms and is under development for use in pediatric patients. Understanding drug pharmac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::936a5f263f3784a0d3d6b45374b049de
https://pure.au.dk/portal/da/publications/the-pharmacokinetics-safety-and-tolerability-of-mirabegron-in-children-and-adolescents-with-neurogenic-detrusor-overactivity-or-idiopathic-overactive-bladder-and-development-of-a-population-pharmacokinetic-modelbased-pediatric-dose-estimation(ef3ee9a0-9ef8-4f65-bbad-09ad22a6d4bc).html